AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37897566 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 106
Study 37897566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic treatment
Number of subjects: 106
Study 37897566 — intervention group
Group type: EXPERIMENTAL
Intervention: D. welbionis abundance
Number of subjects: 106
Study 37897566 — intervention group
Group type: COMPARATOR
Intervention: In vitro effect of metformin
Number of subjects: 106
Study 37897566 — intervention group
Group type: EXPERIMENTAL
Intervention: D. welbionis J115 in mice
Number of subjects: 106
Study 37897713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution diffusion-weighted imaging (hrDWI) (slice thickness: 2.5-3 mm)
Number of subjects: 321
Study 37897713 — intervention group
Group type: COMPARATOR
Intervention: Standard diffusion-weighted imaging (standard DWI) (slice thickness: 5-6 mm)
Number of subjects: 321
Study 37897713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution diffusion-weighted imaging (hrDWI)
Number of subjects: 321
Study 37897713 — intervention group
Group type: COMPARATOR
Intervention: Standard diffusion-weighted imaging (standard DWI)
Number of subjects: 321
Study 37897713 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of hrDWI vs. standard DWI
Number of subjects: 321
Study 37897713 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI field strength (1.5 T vs. 3 T)
Number of subjects: 321
Study 37897800 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza patients with probable IAPA
Number of subjects: 55
Study 37897800 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza patients with IAPA
Number of subjects: 55
Study 37897800 — intervention group
Group type: COMPARATOR
Intervention: Influenza patients without IAPA
Number of subjects: 55
Study 37897866 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA profiling using the Foundation One Liquid CDx Assay (324 genes, blood tumour mutational burden [bTMB], microsatellite instability status)
Number of subjects: 140
Study 37897866 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Number of subjects: 140
Study 37897866 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched therapy recommended by multidisciplinary tumor board (MTB)
Number of subjects: 140
Study 37897866 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment based on genomic profiling
Number of subjects: 140
Study 37897866 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR3 alterations
Number of subjects: 140
Study 37897888 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior falls
Number of subjects: 541
Study 37897888 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Timed Up and Go score
Number of subjects: 541
Study 37898137 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents
Number of subjects: 1300
Study 37898137 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents
Number of subjects: 1300
Study 37898146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PrEP (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate)
Number of subjects: 247
Study 37898146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine ring
Number of subjects: 247
Study 37898146 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 247
Study 37898146 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial results
Number of subjects: 247
Study 37898148 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 BA.4/5 bivalent booster
Number of subjects: 123419
Study 37898148 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 BA.4/5 bivalent booster for XBB-related infections
Number of subjects: 123419
Study 37898148 — intervention group
Group type: COMPARATOR
Intervention: At least two doses of wild-type mRNA vaccine alone
Number of subjects: 123419
Study 37898152 — intervention group
Group type: EXPERIMENTAL
Intervention: Restful Jaw device (PEP Design; Saint Paul)
Number of subjects: 169
Study 37898152 — intervention group
Group type: COMPARATOR
Intervention: Dental Assistant (DA) support
Number of subjects: 169
Study 37898184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod (OZA), oral, once daily, incremental dosage for a maximum of 14 days
Number of subjects: 43
Study 37898184 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 43
Study 37898410 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-2034 low-dose (30 μg of mRNA)
Number of subjects: 40
Study 37898410 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-2034 high-dose (50 μg of mRNA)
Number of subjects: 40
Study 37898410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.3 ml type 5 adenovirus vector for low-dose; 0.5 ml type 5 adenovirus vector for high-dose)
Number of subjects: 40
Study 37898434 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholegrain oats and rye (WG)
Number of subjects: 55
Study 37898434 — intervention group
Group type: COMPARATOR
Intervention: Refined grain (RG)
Number of subjects: 55
Study 37898484 — intervention group
Group type: EXPERIMENTAL
Intervention: Call-to-entry rate
Number of subjects: 1075
Study 37898484 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacted potential participants
Number of subjects: 1075
Study 37898484 — intervention group
Group type: EXPERIMENTAL
Intervention: Responded to recruitment
Number of subjects: 1075
Study 37898488 — intervention group
Group type: EXPERIMENTAL
Intervention: Spared mediastinal lymph node dissection
Number of subjects: 1362
Study 37898488 — intervention group
Group type: COMPARATOR
Intervention: Mediastinal lymph node dissection
Number of subjects: 1362
Study 37898715 — intervention group
Group type: EXPERIMENTAL
Intervention: High myopia (HM) eyes
Number of subjects: 1088
Study 37898715 — intervention group
Group type: EXPERIMENTAL
Intervention: Average MOSH
Number of subjects: 1088
Study 37898715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal MOSH
Number of subjects: 1088
Study 37898715 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MOSH in superior direction
Number of subjects: 1088
Study 37898715 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MOSH in inferior direction
Number of subjects: 1088
Study 37898741 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home, self-administered COVID-19 testing kits distributed to participants.
Number of subjects: 40000
Study 37898741 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on COVID-19 mitigation and health-promoting resources provided to participants.
Number of subjects: 40000
Study 37898741 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit for community engagement in distributing COVID-19 tests.
Number of subjects: 40000
Study 37898741 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing results from the distributed kits.
Number of subjects: 40000
Study 37898741 — intervention group
Group type: EXPERIMENTAL
Intervention: YMTT protocol coupled with local resourcing.
Number of subjects: 40000
Study 37898759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring during mechanical ventilation according to SafeBoosC treatment guideline.
Number of subjects: 3000
Study 37898759 — intervention group
Group type: COMPARATOR
Intervention: Usual care without cerebral oximetry.
Number of subjects: 3000
Study 37898781 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based self-management intervention (AEGORA) via Sidekick app with weekly prompts
Number of subjects: 120
Study 37898781 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based self-management intervention (AEGORA) via Sidekick app with monthly prompts
Number of subjects: 120
Study 37898781 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based self-management intervention (AEGORA)
Number of subjects: 120
Study 37898781 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 37898978 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home HIV/STI testing with a counselor via video chat
Number of subjects: 474
Study 37898978 — intervention group
Group type: COMPARATOR
Intervention: In-person HIV/STI testing
Number of subjects: 474
Study 37898978 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma-focused counseling
Number of subjects: 474
Study 37898978 — intervention group
Group type: COMPARATOR
Intervention: Health information counseling
Number of subjects: 474
Study 37899137 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 163
Study 37899137 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 163
Study 37899143 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based survey
Number of subjects: 2000
Study 37899143 — intervention group
Group type: COMPARATOR
Intervention: In-person survey
Number of subjects: 2000
Study 37899145 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and fetal health and development during pregnancy
Number of subjects: 823
Study 37899153 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction and learning activities (not specifically detailed in the abstract)
Number of subjects: 56
Study 37899153 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' beliefs and practices regarding child development
Number of subjects: 56
Study 37899153 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' roles in child development
Number of subjects: 56
Study 37899153 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to interaction and learning activities
Number of subjects: 56
Study 37899297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus triplet therapy with venetoclax, azacitidine, and homoharringtonine (VAH)
Number of subjects: 51
Study 37899366 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir prophylaxis
Number of subjects: 0
Study 37899366 — intervention group
Group type: COMPARATOR
Intervention: Maribavir preemptive therapy
Number of subjects: 0
Study 37899366 — intervention group
Group type: COMPARATOR
Intervention: Immune-guided prophylaxis
Number of subjects: 0
Study 37899366 — intervention group
Group type: COMPARATOR
Intervention: Maribavir
Number of subjects: 0
Study 37899433 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pharmaceutical-grade biotin (100 mg taken orally three times a day over a maximum of 52 weeks)
Number of subjects: 15
Study 37899433 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pharmaceutical-grade biotin
Number of subjects: 15
Study 37899452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine 18
Number of subjects: 67
Study 37899464 — intervention group
Group type: EXPERIMENTAL
Intervention: WM atypical development index in autistic children
Number of subjects: 191
Study 37899464 — intervention group
Group type: COMPARATOR
Intervention: Subgroup comparison of WM atypical development index
Number of subjects: 191
Study 37899464 — intervention group
Group type: COMPARATOR
Intervention: Threshold-free cluster enhancement-based two-sample t-test for WM microstructures
Number of subjects: 191
Study 37899477 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week program of physical exercise of resistance and muscular strength (8-WVP)
Number of subjects: 0
Study 37899481 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept arm (tacrolimus, belatacept, and prednisone through day 89, then belatacept, mycophenolate mofetil, and prednisone for the remainder of year 1)
Number of subjects: 27
Study 37899481 — intervention group
Group type: COMPARATOR
Intervention: Control arm (tacrolimus, mycophenolate mofetil, and prednisone)
Number of subjects: 27
Study 37899481 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept arm
Number of subjects: 27
Study 37899481 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 27
Study 37899488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon anesthesia
Number of subjects: 67
Study 37899488 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 67
Study 37899826 — intervention group
Group type: EXPERIMENTAL
Intervention: IHAT (nanoparticulate iron hydroxide adipate tartrate)
Number of subjects: 246
Study 37899826 — intervention group
Group type: EXPERIMENTAL
Intervention: FS (ferrous sulfate)
Number of subjects: 246
Study 37899826 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP (iron supplement)
Number of subjects: 246
Study 37899826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 37899826 — intervention group
Group type: EXPERIMENTAL
Intervention: FS administered as a single weekly dose of 420 mg Fe
Number of subjects: 246
Study 37899826 — intervention group
Group type: EXPERIMENTAL
Intervention: FS administered daily at 60 mg Fe/day
Number of subjects: 246
Study 37899826 — intervention group
Group type: EXPERIMENTAL
Intervention: FS plus a micronutrient powder (MNP) administered daily at 60 mg Fe/day
Number of subjects: 246
Study 37900149 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 180
Study 37900149 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 180
Study 37900564 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial reservoir strain (LASr)
Number of subjects: 2712
Study 37900564 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-PEFF score
Number of subjects: 2712
Study 37900595 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety group
Number of subjects: 99
Study 37900595 — intervention group
Group type: COMPARATOR
Intervention: No anxiety group
Number of subjects: 99
Study 37900725 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal high-definition transcranial direct current stimulation (HD-tDCS) over the ipsilesional primary motor cortex (M1)
Number of subjects: 8
Study 37900725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS over contralesional dorsal premotor cortex (PMd)
Number of subjects: 8
Study 37900725 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study 37900725 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal and cathodal HD-tDCS
Number of subjects: 8
Study 37900725 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 8
Study 37900876 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment + Dry Needling (DN)
Number of subjects: 0
Study 37900876 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 37900953 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute upper-body exercise in the cold
Number of subjects: 0
Study 37901346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 and 300 mg every 2 weeks
Number of subjects: 0
Study 37901346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37901358 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention using Nordic walking poles, personalized physician exercise prescriptions, pedometers, and access to exercise videos.
Number of subjects: 150
Study 37901358 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention using Nordic walking poles.
Number of subjects: 150
Study 37901358 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (dialysis unit staff encouragement to exercise).
Number of subjects: 150
Study 37901368 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic Care App
Number of subjects: 58
Study 37901368 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study 37901478 — intervention group
Group type: EXPERIMENTAL
Intervention: ED PLUS
Number of subjects: 29
Study 37901478 — intervention group
Group type: COMPARATOR
Intervention: CGA
Number of subjects: 29
Study 37901478 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 29
Study 37901795 — intervention group
Group type: EXPERIMENTAL
Intervention: Active light-based 40 Hz brain stimulation
Number of subjects: 62
Study 37901795 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 62
Study 37902089 — intervention group
Group type: EXPERIMENTAL
Intervention: H-BC (1600 mg PP)
Number of subjects: 0
Study 37902089 — intervention group
Group type: EXPERIMENTAL
Intervention: L-BC (800 mg PP)
Number of subjects: 0
Study 37902089 — intervention group
Group type: EXPERIMENTAL
Intervention: SO (800 mg PP)
Number of subjects: 0
Study 37902089 — intervention group
Group type: EXPERIMENTAL
Intervention: BC + SO (1600 mg PP)
Number of subjects: 0
Study 37902089 — intervention group
Group type: EXPERIMENTAL
Intervention: BC + F (800 mg PP)
Number of subjects: 0
Study 37902089 — intervention group
Group type: EXPERIMENTAL
Intervention: F (1.5 g fibre)
Number of subjects: 0
Study 37902089 — intervention group
Group type: COMPARATOR
Intervention: CON (placebo)
Number of subjects: 0
Study 37902089 — intervention group
Group type: COMPARATOR
Intervention: CON2 (placebo)
Number of subjects: 0
Study 37902107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose- and acesulfame-potassium-containing diet soda, consumed three times daily for 1 week
Number of subjects: 0
Study 37902144 — intervention group
Group type: EXPERIMENTAL
Intervention: SavvyWire guidewire
Number of subjects: 121
Study 37902150 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-based PCI (n=204)
Number of subjects: 305
Study 37902150 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography-based PCI (n=101)
Number of subjects: 305
Study 37902150 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR guidance (subgroup of physiology-based PCI)
Number of subjects: 305
Study 37902150 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcatheter-derived FFR guidance (subgroup of physiology-based PCI)
Number of subjects: 305
Study 37902726 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB080 (10 mg every 4 weeks, 30 mg every 4 weeks, 60 mg every 4 weeks, 115 mg every 12 weeks)
Number of subjects: 46
Study 37902726 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB080 (60 mg every 12 weeks, 115 mg every 12 weeks) during long-term extension
Number of subjects: 46
Study 37902726 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB080 (tau PET)
Number of subjects: 46
Study 37902726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 37902732 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady concentration PD with 11 g/h glucose dose
Number of subjects: 8
Study 37902732 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady concentration PD with 14 g/h glucose dose
Number of subjects: 8
Study 37902732 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady concentration PD with 20 g/h glucose dose
Number of subjects: 8
Study 37902732 — intervention group
Group type: COMPARATOR
Intervention: Standard 4-hour CAPD dwell with 2 L of 2.5% dextrose solution (control)
Number of subjects: 8
Study 37902733 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) monitoring
Number of subjects: 492
Study 37902733 — intervention group
Group type: COMPARATOR
Intervention: Site-specific usual care
Number of subjects: 492
Study 37902744 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention including a decision-aid booklet personalized based on age, sex, prior screening, and comorbidity.
Number of subjects: 431
Study 37902744 — intervention group
Group type: COMPARATOR
Intervention: Multilevel intervention including a screening informational booklet.
Number of subjects: 431
Study 37902748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse care management intervention including salary for a full-time OUD nurse care manager, training and technical assistance for nurse care managers, and agreement from 3 or more PC clinicians to prescribe buprenorphine.
Number of subjects: 130623
Study 37902748 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) clinics.
Number of subjects: 130623
Study 37902777 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx intervention (low-intensity, electronic medical record-integrated social care assistance)
Number of subjects: 637
Study 37902777 — intervention group
Group type: COMPARATOR
Intervention: Usual care (admission brochure about hospital-based free food options and nonsystematic provision of resource information)
Number of subjects: 637
Study 37902814 — intervention group
Group type: EXPERIMENTAL
Intervention: PAW Toolkit and telephone support calls from an occupational therapist
Number of subjects: 120
Study 37902814 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (standard support from their employer)
Number of subjects: 120
Study 37902819 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated BP monitor
Number of subjects: 660
Study 37902819 — intervention group
Group type: COMPARATOR
Intervention: Nonintegrated BP monitor (Control)
Number of subjects: 660
Study 37902830 — intervention group
Group type: EXPERIMENTAL
Intervention: Vuse Solo ENDS
Number of subjects: 75
Study 37902830 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-use group
Number of subjects: 75
Study 37902830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-, moderate-, and high-use groups
Number of subjects: 75
Study 37902861 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor signaling inhibitors (ARSi)
Number of subjects: 9
Study 37902990 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel anti-NRP2 antibody
Number of subjects: 0
Study 37903112 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Weizhong (BL40)
Number of subjects: 140
Study 37903112 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Chize (LU5)
Number of subjects: 140
Study 37903112 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Weizhong (BL40)
Number of subjects: 140
Study 37903112 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Chize (LU5)
Number of subjects: 140
Study 37903112 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (Acupuncture and Moxibustion)
Number of subjects: 140
Study 37903153 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing program
Number of subjects: 234
Study 37903153 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of oral hygiene
Number of subjects: 234
Study 37903153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar intake
Number of subjects: 234
Study 37903153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 234
Study 37903153 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing frequency
Number of subjects: 234
Study 37903316 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing total gastrectomy (RRTG)
Number of subjects: 126